In this segment, Bradley J. Monk, MD; Robert L. Coleman, MD; and Angeles Alvarez Secord, MD, examine the role of poly-ADP ribose polymerase (PARP) inhibitor, olaparib, in the treatment of advanced ovarian cancer.